onr:"swepub:oai:prod.swepub.kib.ki.se:236097728"
Search: onr:"swepub:oai:prod.swepub.kib.ki.se:236097728" > Empagliflozin reduc...
- 1 of 1
- Previous record
- Next record
- To hitlist
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study
-
- Nyström, T (author)
- Karolinska Institutet
- Toresson Grip, E (author)
- Gunnarsson, J (author)
- show more...
- Casajust, P (author)
- Karlsdotter, K (author)
- Skogsberg, J (author)
- Ustyugova, A (author)
- show less...
- (creator_code:org_t)
- 2022
- 2022
- English.
- In: Diabetes, obesity & metabolism. - 1463-1326.
- Journal article (peer-reviewed)
Subject headings
Close
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Diabetes, obesity & metabolism (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Nyström, T
- Toresson Grip, E
- Gunnarsson, J
- Casajust, P
- Karlsdotter, K
- Skogsberg, J
- show more...
- Ustyugova, A
- show less...
- Articles in the publication
- Diabetes, obesit ...
- By the university
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
